Literature DB >> 7642315

Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit.

R E Begue1, G Castellares, C Cabezas, J L Sanchez, R Meza, D M Watts, D N Taylor.   

Abstract

Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.

Mesh:

Substances:

Year:  1995        PMID: 7642315      PMCID: PMC173519          DOI: 10.1128/iai.63.9.3726-3728.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  PASSIVE SERUM PROTECTION OF THE INFANT RABBIT AGAINST EXPERIMENTAL CHOLERA.

Authors:  O R MCINTYRE; J C FEELEY
Journal:  J Infect Dis       Date:  1964-12       Impact factor: 5.226

2.  Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.

Authors:  S J Cryz; M M Levine; G Losonsky; J B Kaper; B Althaus
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

3.  Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

Authors:  J Sanchez; J Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.

Authors:  R I Glass; A M Svennerholm; M R Khan; S Huda; M I Huq; J Holmgren
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

Review 5.  Vibrio cholerae vaccines.

Authors:  J B Kaper
Journal:  Rev Infect Dis       Date:  1989 May-Jun

6.  B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.

Authors:  J D Clemens; B F Stanton; J Chakraborty; D A Sack; M R Khan; S Huda; F Ahmed; J R Harris; M Yunus; M U Khan
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

7.  Field trial of oral cholera vaccines in Bangladesh.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; B F Stanton; B A Kay; M U Khan; M Yunus; W Atkinson
Journal:  Lancet       Date:  1986-07-19       Impact factor: 79.321

8.  Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up.

Authors:  J D Clemens; J R Harris; D A Sack; J Chakraborty; F Ahmed; B F Stanton; M U Khan; B A Kay; N Huda; M R Khan
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

9.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

10.  Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli.

Authors:  A M Svennerholm; J Holmgren; R Black; M Levine; M Merson
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

  10 in total
  3 in total

1.  Tonsillar application of formalin-killed cells of Streptococcus sobrinus reduces experimental dental caries in rabbits.

Authors:  T Fukuizumi; H Inoue; T Tsujisawa; C Uchiyama
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 2.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.

Authors:  Suman Kanungo; Anna Lena Lopez; Mohammad Ali; Byomkesh Manna; Deok Ryon Kim; Tanmay Mahapatra; Jan Holmgren; Mandeep S Dhingra; Thomas F Weirzba; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens; Dipika Sur
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.